Evidence map›Paper›PMID 23303673›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2013

Proteolysis breaks tolerance toward intact α345(IV) collagen, eliciting novel anti-glomerular basement membrane autoantibodies specific for α345NC1 hexamers.

Florina Olaru, Xu-Ping Wang, Wentian Luo, Linna Ge, Jeffrey H Miner, Sandra Kleinau, Xochiquetzal J Geiger, Andrew Wasiluk, Laurence Heidet, A Richard Kitching and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  3. Atypical Anti-Glomerular Basement Membrane Disease.Kidney international reports · 2023
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.Annals of the New York Academy of Sciences · 2018
    Review
  9. Article
  10. Basement membranes and autoimmune diseases.Matrix biology : journal of the International Society for Matrix Biology · 2017
    Review
  11. Article
  12. Article
  13. Neonatal Fc receptor promotes immune complex-mediated glomerular disease.Journal of the American Society of Nephrology : JASN · 2014
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Florina OlaruDivision of Nephrology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Xu-Ping Wang
Wentian Luo
Linna Ge
Jeffrey H Miner
Sandra Kleinau
Xochiquetzal J Geiger
Andrew Wasiluk
Laurence Heidet
A Richard Kitching
Dorin-Bogdan Borza
Vanderbilt University · USHôpital Necker-Enfants Malades · FRMayo Clinic in Florida · USMonash University · AUUppsala University · SEWashington University in St. Louis · USWinnMed · US

Funding

Washington University Center for Kidney Disease ResearchP30DK079333 · NIDDK · WASHINGTON UNIVERSITY · PI HAMMERMAN, MARC RANDALL · 2007 to 2011
$5.1M
Molecular pathogenesis of anti-glomerular basement membrane nephritisR01DK080799 · NIDDK · VANDERBILT UNIVERSITY · PI BORZA, DORIN-BOGDAN · 2008 to 2012
$1.6M
NIDDK NIH HHS P30 DK079333NIDDK NIH HHS R01 DK080799
6 · The paper itself

Abstract

Goodpasture disease is an autoimmune kidney disease mediated by autoantibodies against noncollagenous domain 1 (NC1) monomers of α3(IV) collagen that bind to the glomerular basement membrane (GBM), usually causing rapidly progressive glomerulonephritis (GN). We identified a novel type of human IgG4-restricted anti-GBM autoantibodies associated with mild nonprogressive GN, which specifically targeted α345NC1 hexamers but not α3NC1 monomers. The mechanisms eliciting these anti-GBM autoantibodies were investigated in mouse models recapitulating this phenotype. Wild-type and FcγRIIB(-/-) mice immunized with autologous murine GBM NC1 hexamers produced mouse IgG1-restricted autoantibodies specific for α345NC1 hexamers, which bound to the GBM in vivo but did not cause GN. In these mice, intact collagen IV from murine GBM was not immunogenic. However, in Col4a3(-/-) Alport mice, both intact collagen IV and NC1 hexamers from murine GBM elicited IgG Abs specific for α345NC1 hexamers, which were not subclass restricted. As heterologous Ag in COL4A3-humanized mice, murine GBM NC1 hexamers elicited mouse IgG1, IgG2a, and IgG2b autoantibodies specific for α345NC1 hexamers and induced anti-GBM Ab GN. These findings indicate that tolerance toward autologous intact α345(IV) collagen is established in hosts expressing this Ag, even though autoreactive B cells specific for α345NC1 hexamers are not purged from their repertoire. Proteolysis selectively breaches this tolerance by generating autoimmunogenic α345NC1 hexamers. This provides a mechanism eliciting autoantibodies specific for α345NC1 hexamers, which are restricted to noninflammatory IgG subclasses and are nonnephritogenic. In Alport syndrome, lack of tolerance toward α345(IV) collagen promotes production of alloantibodies to α345NC1 hexamers, including proinflammatory IgG subclasses that mediate posttransplant anti-GBM nephritis.

Indexed as

Antibody SpecificityImmune ToleranceProteolysisAnimalsAnti-Glomerular Basement Membrane DiseaseAutoantibodiesAutoantigensCollagen Type IVDisease Models, AnimalEpitopesFemaleHEK293 CellsHumansImmunoglobulin GMaleMiceAutoantibodiesAutoantigensCollagen Type IVEpitopesImmunoglobulin Gtype IV collagen alpha3 chain

Identifiers

PMID23303673
PMCPMC3563930
OpenAlexW2133890245

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.